Eli Lilly completes acquisition of Centessa Pharmaceuticals as it pushes orexin receptor 2 drugs

Eli Lilly and Company has completed its acquisition of Centessa Pharmaceuticals, according to a report published Tuesday by Yahoo Finance. The deal closed on June 24, with Lilly indicating that it wants to use Centessa’s assets to advance its work in orexin receptor 2 agonists, a drug approach aimed at modulating the brain’s orexin system, which is associated with alertness and sleep regulation.

Lilly, which trades on the New York Stock Exchange under the ticker LLY, framed the transaction as a way to deepen its pipeline efforts around orexin receptor 2 biology. Orexin receptor 2 agonists are designed to target a specific receptor involved in regulating wakefulness, with the broader goal of producing clinical effects that can help manage sleep-related conditions. In practical terms, the program focus suggests Lilly is trying to strengthen its competitive position in a segment where mechanism-driven treatments are often judged on both efficacy and tolerability.

The Yahoo Finance piece characterized the move as part of Lilly’s broader strategy to develop and bring forward medicines based on specific scientific pathways. By completing the acquisition, Lilly is effectively bringing Centessa’s research and related development work into its own organization, which can shorten decision cycles if Lilly chooses to prioritize the acquired program(s) within its existing portfolio.

While the report indicates the acquisition is now complete, it does not provide in the text available here key deal terms that investors typically look for, such as the purchase price, the structure of the consideration, or how much of Centessa’s cash and liabilities (if any) were assumed by Lilly. It also does not specify the status of the relevant orexin receptor 2 assets, such as whether they are in preclinical testing or have progressed into human trials.

In the absence of those specifics, the most concrete takeaway from the reported update is timing and strategic direction: the acquisition has closed as of June 24, and Lilly’s stated rationale is to advance orexin receptor 2 agonists. For a large pharma company like Lilly, acquisitions can be a lever to add pipeline depth quickly, particularly when internal discovery programs are taking time to mature.

For the healthcare sector, the announcement is another announcement that companies continue to invest in central nervous system targets tied to sleep and related disorders. Mechanism-focused classes, including orexin pathway drugs, often attract interest because they can, in theory, provide more targeted effects than broader sedating approaches. The Centessa tie-in suggests Lilly intends to maintain momentum in that scientific area rather than wait for new candidates to emerge entirely from internal research.

What remains unclear from the available reporting is how Lilly plans to integrate Centessa’s programs operationally and what the near-term milestones will be. Without disclosures such as development timelines, trial phase information, or any regulatory plans, it is difficult to assess the speed at which the orexin receptor 2 work could translate into clinical readouts.

Investors and observers may watch for follow-up disclosures from Lilly, including updates on the acquired program’s stage, any trial starts or planned endpoints, and how management characterizes the acquisition’s contribution to the pipeline. In addition, the company may provide more detail on whether it expects the Centessa-related assets to complement existing Lilly neuroscience efforts, or whether it will reorganize resources around the orexin receptor 2 focus.